Integrating these lifestyle changes can provide a holistic and sustainable approach to weight management and metabolic health, reducing the reliance on medications and highlighting the power of dietary and behavioral modifications in achieving lasting health outcomes
This finding related to combination therapy concurs with the study by Shankar and colleagues, which showed that patients who received combination therapy with a CTLA-4 inhibitor and PD-1/PD-L1 inhibitor had an increased risk for multisystem immune-related adverse events
Factors such as starting weight, dosage, diet, activity level, and individual metabolism all play a role
Dietary modifications can also prove beneficial
Once-weekly subcutaneous retatrutide administration heightened the risk of gastrointestinal and hypersensitivity incidents, typically non-severe
In females, the GLP-1 receptor agonists should not be taken during pregnancy or while breastfeeding, Lee said